$21 million public-private project led by the Foundation for the National Institutes of Health (FNIH) will see government agencies, nonprofits and industry giants hunt for biomarkers that distinguish Parkinson’s diseases from similar conditions.
GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting the largest head-to-head, randomised clinical trial (RCT) of the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared against the 3-drug regimen, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]) at the 25th International AIDS Conference in Munich, Germany (22 – 26 July). The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options alongside its next-generation pipeline assets.
BRUSSELS, July 17 (Reuters) - Europe's second-top court on Wednesday said the European Commission did not give the public sufficient access to the purchase agreements for COVID-19 vaccines during the pandemic, upholding a challenge brought by EU lawmakers against the EU executive's handling of the deals.
GSK HQ officially returns to central London after decades in city’s suburbs
The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza season.
GSK approached the high court against Elder Laboratories early this year for alleged infringement of trademark, including usage of identical product names, trademarks and packaging. GSK issued several notices to Elder before approaching the court seeking a restraining order.
GENEVA and AMSTERDAM, July 9, 2024 /PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces expansion of the clinical trial program for lead pipeline asset, roginolisib. Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in combination with dostarlimab in NSCLC.
The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastrointestinal therapies. According to market researcher Pharmarack, these therapies saw double-digit growth compared to June 2023.
COPENHAGEN, Denmark , July 8, 2024 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announces that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio ('Myricx'), the largest European biotech Series A financing this year. Myricx Bio is a UK biotech company focusing on the discovery and development of a novel payload class for antibody-drug conjugates (ADCs).
GSK plc and Medicines for Malaria Venture (MMV) announce that the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria – tafenoquine, co-administered with chloroquine for radical cure, has now been launched in both Thailand and Brazil, in support of malaria elimination efforts.